@FiercePharma: No generics push for AZ, Brennan says. Report | Follow @FiercePharma
> The E.U. has cleared Abbott Laboratories' purchase of the Belgian company Solvay's pharmaceuticals unit--on the condition that Solvay's cystic fibrosis testing business be sold. Report
> Net profits at 25 leading Indian drugmakers are set to soar more than 50 percent this year, while their consolidated revenues will increase 10 percent -14 percent, according to a new analysis. Report
> A Philippines court has denied Pfizer's bid to stop the sale of a generic version of its blockbuster statin drug Lipitor, but another patent infringement case is still under way. Report
> Leerink Swann reaffirmed its "outperform" rating for Pfizer. Report
> Abbott Laboratories announced that the FDA has granted approval of a new heat-resistant tablet formulation of its antiretroviral medication Norvir (ritonavir). Report
Biotech News
@FierceBiotech: Roche diabetes drug taspoglutide performs like a blockbuster in Phase III. Article | Follow @FierceBiotech
@JohnCFierce: My take on taspoglutide: Roche knows it has a winner and is drawing out the data parade for max attention. Follow @JohnCFierce
> Merck has handed back rights to Anacor Pharmaceuticals' anti-fungal treatment, AN2690. Story
> International businessman Eugene Melnyk (photo) is considering a number of financing options for his company Trimel BioPharma--including an IPO, Dow Jones reports. Report
> Curis will receive $8 million in milestone payments from its Swiss partner Debiopharm after French authorities approved a CTA for a study of Debio 0932, a potential treatment for tumors. Story
> Watch the Medicines Company shrink. Just one month after announcing a 10 percent reduction in its 300+ person staff, the Parsippany, NJ-based developer said today that it's axing another 43 jobs, or 26 percent of its field-based workforce. Article
> When Pfizer refocused its ops in November, it left about 600 of its 1,000 employees in the St. Louis area without a job. But St. Louis University doesn't want to see that talent go to waste. Report
> Both Shire Pharmaceuticals and Protalix have rolled out a fresh barrage of promising late-stage data for their next-gen Gaucher disease drugs, with each taking another big step toward a market that delivers $1.2 billion a year to Genzyme. Story
And Finally... Just in time for Valentine's Day, researchers find that eating chocolate may lower the risk of stroke. Report